Boston Scientific Corp forecast modest 2026 revenue growth and profit just below Wall Street expectations on Wednesday, overshadowing a strong fourth-quarter performance and sending its shares down more than 11% in premarket trading.
February 4, 2026 - 15:56
By Pharos Investment Advisors Comments are Off
Boston Scientific Corp forecast modest 2026 revenue growth and profit just below Wall Street expectations on Wednesday, overshadowing a strong fourth-quarter performance and sending its shares down more than 11% in premarket trading.
January 15, 2026 - 15:36
By Pharos Investment Advisors Comments are Off
Boston Scientific is spending $14.5 billion in cash and stock to buy Penumbra, another medical-device maker that makes products used in minimally invasive procedures to treat conditions such as pulmonary embolism and stroke.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved